MENU
+Compare
IBRN
ETF ticker: NYSE ARCA
AS OF
Jul 31 closing price
Price
$23.34
Change
+$0.39 (+1.70%)
Net Assets
3.48M

IBRN stock forecast, quote, news & analysis

The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U... Show more

Category: #Health
IBRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for IBRN with price predictions
Aug 01, 2025

IBRN's RSI Indicator leaves overbought zone

The 10-day RSI Indicator for IBRN moved out of overbought territory on July 25, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 11 instances where the indicator moved out of the overbought zone. In of the 11 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 34 cases where IBRN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IBRN broke above its upper Bollinger Band on July 17, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IBRN entered a downward trend on July 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 16, 2025. You may want to consider a long position or call options on IBRN as a result. In of 54 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IBRN just turned positive on July 17, 2025. Looking at past instances where IBRN's MACD turned positive, the stock continued to rise in of 29 cases over the following month. The odds of a continued upward trend are .

IBRN moved above its 50-day moving average on July 17, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for IBRN crossed bullishly above the 50-day moving average on July 22, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Biogen (NASDAQ:BIIB), Intra-Cellular Therapies (NASDAQ:ITCI), Sarepta Therapeutics (NASDAQ:SRPT), Avadel Pharmaceuticals plc (NASDAQ:AVDL).

Industry description

The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience. The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index. It is non-diversified.

Market Cap

The average market capitalization across the iShares Neuroscience and Healthcare ETF ETF is 3.18B. The market cap for tickers in the group ranges from 82.57M to 41.57B. ARGX holds the highest valuation in this group at 41.57B. The lowest valued company is ANRO at 82.57M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Neuroscience and Healthcare ETF ETF was 0%. For the same ETF, the average monthly price growth was 7%, and the average quarterly price growth was -10%. SRPT experienced the highest price growth at 33%, while ALEC experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the iShares Neuroscience and Healthcare ETF ETF was 4%. For the same stocks of the ETF, the average monthly volume growth was 6% and the average quarterly volume growth was 57%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 56
P/E Growth Rating: 78
Price Growth Rating: 56
SMR Rating: 89
Profit Risk Rating: 87
Seasonality Score: -19 (-100 ... +100)
View a ticker or compare two or three
IBRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
1-800-474-2737
Web
www.ishares.com